ZVRA vs CLYM
Comparison between Zevra Therapeutics Inc (ZVRA, Company) and Eliem Therapeutics Inc (CLYM, Company).
Both ZVRA and CLYM are from the Healthcare sector.
5-Year PerformanceZVRA has outperformed CLYM, delivering a return of -0.9% compared to -5.4%
ZVRA vs CLYM - Performance Comparison
Key Characteristics
Financial metrics and valuation ratios
ZVRA vs CLYM - Historical Returns
Returns include dividend reinvestment.
ZVRA vs CLYM - Annual Returns (2015 - 2026)
Returns include dividend reinvestment.
| Year | ZVRA | CLYM |
|---|---|---|
| 2026 | +15.59% | +222.13% |
| 2025 | +2.28% | +93.24% |
| 2024 | +22.11% | -35.71% |
| 2023 | +44.59% | -18.43% |
| 2022 | -50.43% | -66.30% |
| 2021 | -16.65% | -34.21% |
| 2020 | +72.84% | N/A |
| 2019 | -80.86% | N/A |
| 2018 | -57.11% | N/A |
| 2017 | +24.62% | N/A |
| 2016 | -83.99% | N/A |
| 2015 | +77.32% | N/A |
ZVRA vs CLYM Drawdown Comparison
The maximum drawdown for ZVRA was -99.27%, occurring on May 22, 2020. This drawdown has not yet recovered.
The maximum drawdown for CLYM was -96.05%, occurring on Apr 8, 2025. This drawdown has not yet recovered.
The current ZVRA drawdown is -97.45%. The current CLYM drawdown is -57.78%.
| Rank | ZVRA | CLYM |
|---|---|---|
| #1 | -99.27% Sep 18, 2015 - May 22, 2020 | -96.05% Sep 7, 2021 - Apr 8, 2025 |
| #2 | -19.68% Jun 22, 2015 - Aug 14, 2015 | -29.96% Aug 11, 2021 - Aug 25, 2021 |
| #3 | -19.23% Aug 17, 2015 - Sep 18, 2015 | -8.25% Aug 30, 2021 - Sep 7, 2021 |
| #4 | -8.72% May 11, 2015 - Jun 1, 2015 | N/A |
| #5 | -4.20% Jun 18, 2015 - Jun 22, 2015 | N/A |
| #6 | -2.87% Jun 15, 2015 - Jun 17, 2015 | N/A |
| #7 | -1.79% Apr 16, 2015 - May 1, 2015 | N/A |
| #8 | -0.97% Jun 4, 2015 - Jun 8, 2015 | N/A |
| #9 | -0.79% May 1, 2015 - May 6, 2015 | N/A |
| #10 | -0.61% Jun 8, 2015 - Jun 10, 2015 | N/A |
| #11 | -0.06% Jun 10, 2015 - Jun 12, 2015 | N/A |
Correlation
Correlation between ZVRA and CLYM is 0.37 which considered as a weak positive correlation - the stocks show a slight tendency to move together.
Select Stocks to Compare
More Comparisons
Compare with similar stocks